Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05380440 · ClinicalTrials.gov registry record · NA

Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR

A NA study of Opioid-Related Disorders and Child Neglect, sponsored by Chestnut Health Systems.

Completed
Registry status
NA
Development phase
241
Enrollment target
1
Study location

NCT05380440 is a NA study of Opioid-Related Disorders and Child Neglect that has completed, run by Chestnut Health Systems. The registered enrollment target is 241 participants, below the 342-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05380440, a NA study of Opioid-Related Disorders and Child Neglect, has completed, sponsored by Chestnut Health Systems.

COMPLETED
Registry status
NA
Development phase
241 participants
Enrollment target
1
Study location

Study Summary

Young parents aged 16 to 30, involved in the DHS system for child welfare or self-sufficiency needs are at risk for opioid use disorder and/or methamphetamine use disorder (OUD; MUD). Those identified as engaging in opioid or methamphetamine misuse are at high risk for escalation. Children of parents with OUD and MUD are at-risk for entering into foster care. Oregon is one state particularly affected by this challenge. The proposed research offers one potential solution by adapting and evaluating a recently developed treatment for parental OUD and MUD, for prevention. This study seeks to collaborate with Oregon Department of Humans Services (DHS) leadership to deliver a new outpatient prevention program to high-risk, young, parents. The Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR) program will include community-based mental health, parent management, and ancillary needs treatment, and ongoing monitoring and prevention services for opioid and methamphetamine use. This study will randomize 240 parents, aged 16 to 30, to receive PRE-FAIR or standard case management and referral, in two counties in Oregon. Outcomes will include an evaluation of the effectiveness of PRE-FAIR in addressing risk factors associated with substance use disorders in DHS-involved populations, OUD and MUD outcomes, and implementation outcomes including implementation process and milestones, and program delivery outcomes. Intervention and Implementation costs will be assessed, and the benefit of PRE-FAIR will be evaluated in relation to standard services, but also in relation to capacity and population needs. Study hypotheses are: (1) Parents randomized to PRE-FAIR will be less likely to escalate opioid and/or methamphetamine use, and to receive a diagnosis of OUD and/or MUD; (2) Parents randomized to PRE-FAIR will experience significant reductions in mental health, parent skills, and ancillary needs compared to those receiving standard services; (3) Counties will

Interventions

  • BEHAVIORAL Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR)
  • BEHAVIORAL Standard Case Management and Referral

Study Locations (1)

Oregon

  • Chestnut Health Systems - Eugene

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2021-06-09
Est. Completion 2025-06-02
Phase NA

Sponsor

Chestnut Health Systems

20 total trials

What the Registry Record Tells You About NCT05380440

The ClinicalTrials.gov registry entry for NCT05380440 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 342-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (30% lower). The listed sponsor is Chestnut Health Systems, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR) is the first listed.

NCT05380440 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT05380440 about?

NCT05380440 is a clinical study titled "Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR". Young parents aged 16 to 30, involved in the DHS system for child welfare or self-sufficiency needs are at risk for opioid use disorder and/or methamphetamine use disorder (OUD; MUD). Those identified as engaging in opioid or methamphetamine misuse are at high risk for escalation. Children of parent...

What is the current status of trial NCT05380440?

This trial is currently completed. It is a NA study. The enrollment target is 241 participants. The study started on 2021-06-09. Estimated completion is 2025-06-02.

What conditions does trial NCT05380440 study?

This clinical trial studies the following conditions: Opioid-Related Disorders, Child Neglect, Mental Health Impairment, Stimulant-Related Disorder.

What interventions are being tested in trial NCT05380440?

The interventions under investigation include: Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR) (BEHAVIORAL), Standard Case Management and Referral (BEHAVIORAL).

Who is sponsoring clinical trial NCT05380440?

This trial is sponsored by Chestnut Health Systems, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05380440 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.